These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21513366)

  • 21. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
    Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
    Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
    Romero L; Trenor B; Yang PC; Saiz J; Clancy CE
    J Mol Cell Cardiol; 2015 Oct; 87():271-82. PubMed ID: 26859003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of injectable HPβCD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo.
    Carr DB; McDonnell Moorehead T; Bouchard A; Sprenger CR; Hamilton DA; Lang E; Madden D; Lacouture PG; Wright C
    Clin Ther; 2013 May; 35(5):646-58. PubMed ID: 23578606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced long QT syndrome: a continuing challenge in the field.
    Glatter KA; Hamdan MH; Zhang Q; Chiamvimonvat N
    J Cardiovasc Electrophysiol; 2007 Jul; 18(7):696-7. PubMed ID: 17537200
    [No Abstract]   [Full Text] [Related]  

  • 26. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
    Hoffmann P; Warner B
    J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics.
    Anderson ME; Mazur A; Yang T; Roden DM
    J Pharmacol Exp Ther; 2001 Mar; 296(3):806-10. PubMed ID: 11181910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation.
    Yeung KS; Meanwell NA
    ChemMedChem; 2008 Oct; 3(10):1501-2. PubMed ID: 18696522
    [No Abstract]   [Full Text] [Related]  

  • 29. hERG trafficking inhibition in drug-induced lethal cardiac arrhythmia.
    Nogawa H; Kawai T
    Eur J Pharmacol; 2014 Oct; 741():336-9. PubMed ID: 24998878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.
    Lawrence CL; Bridgland-Taylor MH; Pollard CE; Hammond TG; Valentin JP
    Br J Pharmacol; 2006 Dec; 149(7):845-60. PubMed ID: 17031389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.
    Witchel HJ; Hancox JC
    Clin Exp Pharmacol Physiol; 2000 Oct; 27(10):753-66. PubMed ID: 11022966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of drug induced QT interval prolongation.
    Ponte ML; Keller GA; Di Girolamo G
    Curr Drug Saf; 2010 Jan; 5(1):44-53. PubMed ID: 20210718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-induced hERG block and long QT syndrome.
    Witchel HJ
    Cardiovasc Ther; 2011 Aug; 29(4):251-9. PubMed ID: 20406244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 25th anniversary of the International Long-QT Syndrome Registry: an ongoing quest to uncover the secrets of long-QT syndrome.
    Moss AJ; Schwartz PJ
    Circulation; 2005 Mar; 111(9):1199-201. PubMed ID: 15753228
    [No Abstract]   [Full Text] [Related]  

  • 35. A 2015 focus on preventing drug-induced arrhythmias.
    Bossu A; van der Heyden MA; de Boer TP; Vos MA
    Expert Rev Cardiovasc Ther; 2016; 14(2):245-53. PubMed ID: 26560188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death.
    De Bruin ML; Pettersson M; Meyboom RH; Hoes AW; Leufkens HG
    Eur Heart J; 2005 Mar; 26(6):590-7. PubMed ID: 15637086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular predictors of drug-induced prolongation of the QT interval.
    Dilaveris PE
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of uncertainty in hERG binding mechanism on in silico predictions of drug-induced proarrhythmic risk.
    Lei CL; Whittaker DG; Mirams GR
    Br J Pharmacol; 2024 Apr; 181(7):987-1004. PubMed ID: 37740435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Facilitation of hERG Activation by Its Blocker: A Mechanism to Reduce Drug-Induced Proarrhythmic Risk.
    Furutani K
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
    Rampe D; Roy ML; Dennis A; Brown AM
    FEBS Lett; 1997 Nov; 417(1):28-32. PubMed ID: 9395068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.